Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

ET

Ernexa Therapeutics Inc.

$4.52

+0.09 (+2.03%)

D 23Pipeline Score Richly Valued Pharma · Clinical
Market Cap
7.38 M
EPS
-9.79
P/E Ratio
-
Value Trade
319.73 K
5.85 %
Week
1.57 %
1 Month
-62.3 %
3 Month
-40.74 %
6 Month
-99.99 %
5 Year
-100 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
27.83 K
52 Week Range
3.18 - 71.50
% held by Insiders
41.37 %
% held by Institutions
2.21 %
Enterprise Value
2.35 M
Total Shares
1.63 M
Short %
1.52 %
Float Shares
690.70 K
Company Description
HQ: 1035 CAMBRIDGE STREET, CAMBRID...
Employees:5
https://www.ernexatx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
IND Submission example
IND
—

Subscribe to access the data.

Cell Therapies
Oncology
IND
—

Subscribe to access the data.

Cell Therapies
Oncology
IND
—

Subscribe to access the data.

Cell Therapies
Oncology
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Ernexa Therapeutics Inc.

106Total events
9Upcoming
13Tier-1 (high impact)
2016 – 2026Coverage

Upcoming catalysts 2

TBD
T2Trial Initiation
Subscribe to view catalyst details
ERNA-101
TBD
T3Pre IND Meeting
Subscribe to view catalyst details
ERNA-201

Event history 2

TBD
▲Preclinical PoCERNA-101Preclinical
Subscribe to view catalyst details
TBD
◆IND SubmissionERNA-101IND
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2026-09-30
ERNA-101 (engineered synthetic induced-mesenchymal stem cell therapy)
IND Submission
IND
—
–
–
–
2026-09-30
ERNA-101 (engineered synthetic induced-mesenchymal stem cell therapy)
IND Submission
IND
—
–
–
–
2026-09-30
ERNA-101 (engineered synthetic induced-mesenchymal stem cell therapy)
IND Submission
IND
—
–
–
–
Unlock 3 more historical catalysts
Drug Pipeline Intelligence
D23
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 23%
Micro Cap
(rank 718 of 931)
Percentile Rank
Ernexa Therapeutics Inc. faces pipeline headwinds (23/100), with $240M risk-adjusted pipeline value, led by IRX-2 in Squamous Cell Carcinoma of the Oral Cavity (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IRX-2
Monoclonal antibody		Squamous Cell Carcinoma of the Oral CavityPhase 2NCT0260938614% $240M COMPLETED 105 - -Feb 28, 2022 -Jan 30, 2024
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ERNA-101
immunologically cold tumors
Phase 1
2026-06-17

Complete elimination of detectable tumors; 100% long-term survival through study follow-up; Significant remodeling of the tumor microenvironment from immunosuppressive to immune-activated; Increased infiltration of CD4+ and CD8+ T cells; Enhanced T-cell persistence and anti-tumor activity; Reprogramming of tumor-associated macrophages into a tumor-fighting phenotype; Significant reductions in tumor burden and malignant ascites

Read More

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Read More
ERNA-101
immunologically cold tumors
Phase 1
2026-06-17

Complete elimination of detectable tumors; 100% long-term survival through study follow-up; Significant remodeling of the tumor microenvironment from immunosuppressive to immune-activated; Increased infiltration of CD4+ and CD8+ T cells; Enhanced T-cell persistence and anti-tumor activity; Reprogramming of tumor-associated macrophages into a tumor-fighting phenotype; Significant reductions in tumor burden and malignant ascites

Read More

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Read More
ERNA-101
immunologically cold tumors
Phase 1
2026-06-17

Complete elimination of detectable tumors; 100% long-term survival through study follow-up; Significant remodeling of the tumor microenvironment from immunosuppressive to immune-activated; Increased infiltration of CD4+ and CD8+ T cells; Enhanced T-cell persistence and anti-tumor activity; Reprogramming of tumor-associated macrophages into a tumor-fighting phenotype; Significant reductions in tumor burden and malignant ascites

Read More

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ERNA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ERNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ERNA
Aug 10, 2026
ERNAGeneral
▲ +7.6%on this news

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Ernexa Therapeutics has appointed David Polinsky to its Board of Directors as the company approaches a pivotal stage in its development. With plans for an IND submission for ERNA-101 in Q3 2026 and a Phase 1 clinical study initiation in Q4 2026, the leadership team aims to strengthen its operational infrastructure. Polinsky's extensive experience in biotechnology and corporate governance is expected to guide Ernexa through its upcoming clinical milestones.

Read more →
-ERNA
Jul 24, 2026
ERNAPhases

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

Ernexa Therapeutics' CEO Sanjeev Luther highlights the potential of ERNA-101 in transforming cancer treatment through combination therapies. The therapy aims to target immunologically 'cold' tumors, enhancing the effectiveness of existing immunotherapies. Encouraging preclinical results support its development, with plans for an IND submission in Q3 2026 and a Phase 1 study to follow.

Read more →
-ERNA
Jul 15, 2026
ERNAPhases
▲ +11.1%on this news

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Ernexa Therapeutics announced successful independent validation of its lead therapy, ERNA-101, demonstrating complete tumor clearance and long-term survival in a preclinical study. The combination of ERNA-101 with anti-PD-1 therapy showed significant results, with plans for an IND submission in Q3 2026 and a Phase 1 trial expected in Q4 2026. This study strengthens the foundation for ERNA-101's clinical development.

Read more →
-ERNA
Jul 14, 2026
ERNAPhases
▲ +9.4%on this news· ran to +21% by day 1shared move

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Ernexa Therapeutics is advancing its lead cell therapy candidate, ERNA-101, aimed at treating ovarian cancer. The company plans to submit an IND application in Q3 2026, with a first-in-human Phase 1 study expected to start in Q4 2026. CEO Sanjeev Luther highlighted the potential of ERNA-101 to convert immunologically 'cold' tumors into detectable targets for the immune system. Encouraging preclinical data supports the efficacy of ERNA-101 in tumor clearance and survival rates.

Read more →
-ERNA
Jun 25, 2026
ERNAGeneral
▲ +17.5%on this news

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

Ernexa Therapeutics has launched its CEO Corner platform to provide insights into the company's mission and scientific strategy. The inaugural video features CEO Sanjeev Luther discussing the company's commitment to developing innovative cell therapies for advanced cancer and autoimmune diseases. The platform aims to enhance communication with stakeholders and emphasize the importance of accessibility and affordability in treatment.

Read more →
-ERNA
Jun 17, 2026
ERNAPhases

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Ernexa Therapeutics is advancing its lead oncology candidate, ERNA-101, with a planned IND submission in Q3 2026 and a first-in-human study expected in Q4 2026. The therapy aims to treat immunologically cold tumors, showing promising preclinical results. The company has completed key manufacturing and regulatory milestones, positioning itself for clinical-stage development.

Read more →
-ERNA
Jun 9, 2026
ERNAGeneral
▼ -8%on this news

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Ernexa Therapeutics highlighted the unmet needs in ovarian cancer during a Virtual Investor KOL Connect segment featuring Dr. Ira Winer. The discussion focused on the limitations of current treatments and the potential of ERNA-101, which aims to activate immune responses in the tumor microenvironment. The engineered cell therapy may offer scalable solutions that improve accessibility for patients facing difficult-to-treat cancers.

Read more →
-ERNA
May 27, 2026
ERNAPhases

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Ernexa Therapeutics has made significant strides in the development of its lead candidate, ERNA-101, by completing critical manufacturing milestones and transitioning to GMP manufacturing. The company is on track for an Investigational New Drug (IND) submission in Q3 2026, which will pave the way for its first-in-human clinical study. These advancements reflect Ernexa's commitment to addressing unmet medical needs in cancer and autoimmune diseases.

Read more →
-ERNA
May 20, 2026
ERNAConferences/Events

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Ernexa Therapeutics has released a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, who discusses the challenges in treating ovarian cancer and the potential of ERNA-101. The segment highlights the limitations of current therapies and elevates Ernexa's innovative approach with preclinical data showing successful tumor eradication. Dr. Ratner emphasizes the advantages of the company's engineered allogeneic iMSC platform, which aims to enhance accessibility and efficiency in treatment. This development underscores Ernexa's commitment to addressing significant unmet needs in the cancer treatment landscape.

Read more →
-ERNA
May 11, 2026
ERNAConferences/Events

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

Ernexa Therapeutics has released a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, discussing the challenges in ovarian cancer treatment and the potential of their lead candidate, ERNA-101. The segment emphasizes the need for more effective therapies and outlines how ERNA-101 could enhance patient outcomes. Additionally, the company will participate in a Virtual Investor Closing Bell event on May 13, 2026, to discuss preclinical data for ERNA-101.

Read more →
-ERNA
May 6, 2026
ERNAPhases
▲ +51.4%on this news· ran to +96% by day 1shared move

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

Ernexa Therapeutics announced remarkable preclinical results for its lead cell therapy candidate, ERNA-101, which demonstrated complete tumor elimination and 100% long-term survival in ovarian cancer models. The therapy, in combination with PD-1 blockade, showed significant efficacy by converting the tumor microenvironment from immunosuppressive to immune-activated. With plans to advance ERNA-101 towards human trials, Ernexa aims to address the challenges posed by ovarian cancer treatments traditionally hindered by a non-responsive immune environment. The company intends to explore additional indications for ERNA-101 in other solid tumors as well.

Read more →
-ERNA
Apr 30, 2026
ERNAGeneral
▼ -21.2%on this news

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Ernexa Therapeutics has announced a 1-for-25 reverse stock split effective May 4, 2026, to comply with Nasdaq's minimum bid price requirement. This move aims to enhance the company's financial standing and visibility among investors. The split will adjust the number of shares outstanding while maintaining the rights of existing shares. The company is focused on advancing its clinical programs and strengthening its market position.

Read more →
-ERNA
Mar 31, 2026
ERNAPhases
▲ +5.3%on this news

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Ernexa Therapeutics is advancing its lead product candidate, ERNA-101, toward first-in-human clinical trials anticipated to begin in Q4 2026. The company has demonstrated promising preclinical data showcasing its potential in treating platinum-resistant ovarian cancer. Key regulatory milestones, including an IND submission expected in Q3 2026, are set to support the company's transition from preclinical to clinical stages. Ernexa plans to leverage recent financing to fulfill critical upcoming milestones, positioning itself for significant value creation in the near term.

Read more →
-ERNA
Feb 20, 2026
ERNAConferences/Events
▼ -17.2%on this news

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Ernexa Therapeutics will participate in the Virtual Investor Closing Bell Series on February 25, 2026. CEO Sanjeev Luther will present a corporate overview and engage with investors through a Q&A session. The event aims to enhance transparency and provide insights into Ernexa's innovative cell therapies for cancer and autoimmune diseases.

Read more →
-ERNA
Feb 6, 2026
ERNAGeneral
▼ -44.7%on this news· ran to -56% by day 3

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Ernexa Therapeutics has announced the pricing of a public offering of 21 million shares at $0.50 each, expected to raise $10.5 million. The offering includes warrants with an exercise price of $0.68. Proceeds will be used for development programs and corporate purposes. The closing is anticipated around February 10, 2026, pending customary conditions.

Read more →
-ERNA
Feb 3, 2026
ERNAFDA Updates
▼ -25.8%on this news· ran to -70% by day 3shared move

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Ernexa Therapeutics recently participated in a Virtual Investor segment discussing its successful Pre-IND meeting with the FDA. The meeting confirmed regulatory alignment for its lead cell therapy, ERNA-101, aimed at treating ovarian cancer. The company is on track to submit an Investigational New Drug application and initiate clinical trials in the second half of 2026.

Read more →
-ERNA
Jan 28, 2026
ERNAGeneral
▲ +6.9%on this news

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics has been selected as one of ten global companies for the Japan Entry Acceleration Program (JEAP), a competitive initiative by JETRO. This selection underscores Ernexa's innovative cell therapy platform aimed at treating advanced cancer and autoimmune diseases. The program will provide mentoring and market-entry guidance, enhancing Ernexa's potential in the Japanese market. The company aims to advance its lead therapies, ERNA-101 and ERNA-201, through this initiative.

Read more →
-ERNA
Jan 6, 2026
ERNAFDA Updates

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics has announced a successful Pre-IND meeting with the FDA, indicating strong alignment for initiating their first-in-human trials for ovarian cancer in 2026. The company is currently accelerating operational activities, including tech transfer, to enhance clinical manufacturing readiness. Their lead product, ERNA-101, utilizes engineered induced mesenchymal stem cells for targeted therapy against ovarian cancer. This development reflects significant progress in delivering innovative cell therapies for serious diseases.

Read more →
-ERNA
Dec 8, 2025
ERNAPhases

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Ernexa Therapeutics presented new preclinical data on its cell therapy candidate ERNA-101 at the ASH Annual Meeting, showcasing the ability to reprogram tumor microenvironments to support immune activity. The findings highlight the potential of iPSC-derived mesenchymal stem cells to activate immune responses against cancers, including ovarian cancer. IL-7 and IL-15-secreting iMSCs demonstrated impressive immune cell infiltration and prolonged patient survival in animal models. The company is aiming to advance ERNA-101 into human clinical trials, indicating significant progress in their research efforts.

Read more →
-ERNA
Dec 3, 2025
ERNAGeneral

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

Ernexa Therapeutics has appointed Dr. Ira S. Winer to its Scientific and Medical Advisory Board, enhancing its capabilities in developing cell therapies for advanced cancer and autoimmune diseases. Dr. Winer's expertise in gynecologic oncology and translational science will support the advancement of Ernexa's iMSC platform and its lead program, ERNA-101, towards first-in-human trials. His strategic guidance is expected to help translate innovation into meaningful clinical outcomes.

Read more →
-ERNA
Dec 3, 2025
ERNAConferences/Events

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Ernexa Therapeutics will present data from its cell therapy platform at the 67th American Society of Hematology Annual Meeting in December 2025. This presentation marks a significant milestone for the company, demonstrating the potential of their iMSC technology in cancer treatment. The lead therapy, ERNA-101, aims to enhance immune responses against tumors, particularly in ovarian cancer. The chosen presentation underlines the innovative approach Ernexa is taking in addressing hard-to-treat conditions.

Read more →
-ERNA
Nov 11, 2025
ERNAConferences/Events
▼ -5.4%on this news

Ernexa Therapeutics to Present at Oxford Global’s Cell 2025

Ernexa Therapeutics will present at Cell 2025 in London on November 11-12, 2025. CEO Sanjeev Luther will discuss strategies for preparing cell therapies for clinical use and the challenges in navigating development. The event aims to foster collaboration among industry leaders in bioprocessing and advanced therapies, highlighting the role of AI in innovation.

Read more →
-ERNA
Nov 10, 2025
ERNAGeneral

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Ernexa Therapeutics reported a 44% reduction in operating loss year-over-year, reflecting strong operational execution. The company is advancing its lead program, ERNA-101, toward a Phase 1 study for platinum-resistant ovarian cancer expected in H2 2026. A partnership with Cellipont Bioservices is set to enhance the development of its innovative cell therapies.

Read more →
-ERNA
Nov 6, 2025
ERNAGeneral

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Ernexa Therapeutics has announced a strategic partnership with Cellipont Bioservices to advance its lead cell therapy, ERNA-101, for ovarian cancer. During a recent Virtual Investor segment, CEO Sanjeev Luther highlighted the collaboration's focus on Engineering, Differentiation, and Production activities. This partnership aims to facilitate clinical manufacturing and trials for ERNA-101, which utilizes innovative iPSC technology.

Read more →
-ERNA
Oct 1, 2025
ERNAConferences/Events

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Ernexa Therapeutics will present at the Cell & Gene Meeting on the Mesa on October 7. The presentation will focus on their progress in developing scalable iMSC therapies for cancer and autoimmune diseases. The company aims to highlight its lead therapy, ERNA-101, which targets ovarian cancer, and its approach to providing off-the-shelf treatments. The conference is a key event for advancing cell and gene therapies.

Read more →
-ERNA
Sep 29, 2025
ERNAConferences/Events

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Ernexa Therapeutics announced that its President and CEO, Sanjeev Luther, will present at the 5th Annual iPSC Drug Development Summit on October 1 in Boston. The company is advancing innovative cell therapies, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune diseases. Luther emphasized the potential of their synthetic iMSC approach to transform cell therapy.

Read more →
-ERNA
Sep 17, 2025
ERNAConferences/Events
▼ -5.2%on this news

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Ernexa Therapeutics announced that it will present preclinical data on its lead program, ERNA-101, at the AACR Special Conference in Cancer Research. The oral presentation will focus on how gene-modified iPS-derived MSCs can restore immune activity in high-grade serous ovarian cancer. This research highlights the potential of ERNA-101 to offer new therapeutic avenues in treating difficult tumors.

Read more →
-ERNA
Sep 10, 2025
ERNAGeneral

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Ernexa Therapeutics reported significant operational improvements for the first half of 2025, highlighted by a 51% reduction in operating expenses. The company is advancing its lead cell therapy product, ERNA-101, for ovarian cancer and continues to develop ERNA-201 for autoimmune diseases. These advancements are part of Ernexa's strategy to provide scalable, off-the-shelf cell therapies.

Read more →
-ERNA
Sep 3, 2025
ERNAConferences/Events

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Ernexa Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The presentation will cover the company's business, recent milestones, and its proprietary induced mesenchymal stem cell platform. Ernexa is focusing on two lead programs: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune diseases.

Read more →
-ERNA
Jul 9, 2025
ERNAGeneral

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Ernexa Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirements, allowing its stock to continue trading. The company is focused on advancing its innovative cell therapies, with plans to initiate its first clinical trial in early 2026. Their lead product, ERNA-101, aims to treat ovarian cancer, while ERNA-102 targets autoimmune diseases.

Read more →
-ERNA
Jun 25, 2025
ERNAGeneral
▼ -5.1%on this news

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics has expanded its Scientific Advisory Board to include a combined Scientific and Medical Advisory Board, marking a significant step towards clinical trials for ovarian cancer and autoimmune diseases. The new board members, Dr. Amir Jazaeri and Dr. Anna Jonsson, bring extensive expertise to guide the company's clinical strategies. This move follows Ernexa's strengthened financial position, aimed at accelerating its lead programs.

Read more →
-ERNA
Jun 24, 2025
ERNAGeneral
▼ -17.5%on this newsshared move

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Ernexa Therapeutics announced the successful completion of a second closing under a securities purchase agreement, raising approximately $6 million. The funds will be used for general working capital and to advance the company’s pipeline of cell therapies targeting advanced cancer and autoimmune diseases. The approval for the closing was obtained during the company’s Annual Meeting of Stockholders. Ernexa's lead product, ERNA-101, aims to activate the immune system to combat cancer cells, specifically ovarian cancer.

Read more →
-ERNA
Jun 10, 2025
ERNAGeneral
▼ -18%on this news

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics announced a 1-for-15 reverse stock split effective June 12, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement. This decision was approved by stockholders and is seen as part of the company's efforts to strengthen its financial position. Following the split, existing shareholders will find their shares automatically reclassified, although no fractional shares will be issued. The company is focused on advancing its clinical programs, including cell therapies for advanced cancer and autoimmune diseases.

Read more →
-ERNA
May 28, 2025
ERNAConferences/Events

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics announced new data to be presented at the ASCO Annual Meeting 2025, showcasing its innovative iMSC-based immunotherapy platform. The study, conducted in a mouse model of ovarian cancer, demonstrated significant tumor burden reduction and prolonged survival through the secretion of cytokines IL-7 and IL-15 by the engineered iMSCs. This approach aims to convert immunologically 'cold' tumors into 'hot' ones, potentially offering new treatment avenues for cancer patients. The presentation is scheduled for June 2, 2025, in Chicago, highlighting the company's commitment to advancing their cell therapy products.

Read more →
-ERNA
May 14, 2025
ERNAGeneral
▲ +13.1%on this news

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics has announced the launch of ErnexaTX2, a new subsidiary in Texas to support the development of its lead program, ERNA-101, aimed at treating ovarian cancer. This initiative is part of the company's strategy to streamline operations for anticipated clinical activities starting in 2026. The subsidiary will bolster collaboration with MD Anderson Cancer Center and enhance the company's capacity for clinical manufacturing and regulatory compliance. ERNA-101 is currently on track for IND-enabling studies in 2025, paving the way for future human trials.

Read more →
-ERNA
Apr 29, 2025
ERNAConferences/Events

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Ernexa Therapeutics presented new data at the AACR Annual Meeting 2025, highlighting the potential of their engineered induced mesenchymal stem cells (iMSCs) for treating ovarian cancer. The study demonstrated that these iMSCs can significantly slow tumor growth and enhance immune response by releasing immune-boosting cytokines. If successful, this treatment could provide a more effective and accessible option for patients who don't respond well to existing therapies. Ernexa's lead product, ERNA-101, is designed specifically for this purpose, showing promise in preclinical trials.

Read more →
-ERNA
Apr 22, 2025
ERNAConferences/Events

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Ernexa Therapeutics announced that new data on its lead cell therapy product, ERNA-101, will be presented at the AACR Annual Meeting 2025. The study focuses on its technology designed to directly treat ovarian tumors. Led by experts from MD Anderson Cancer Center, the research aims to optimize immune responses against difficult cancers. The company is positioning ERNA-101 as a significant innovation in cancer therapy, addressing a critical need for patients with limited options.

Read more →
-ERNA
Apr 3, 2025
ERNAGeneral
▼ -5.2%on this news

Ernexa Therapeutics Closes New Funding Round

Ernexa Therapeutics has successfully closed a new funding round, raising approximately $7.25 million through a private placement of about 69.3 million shares. The funding will support the company's ongoing efforts in developing innovative cell therapies targeting ovarian cancer and autoimmune diseases. This follows a prior investment round in 2024, indicating strong investor confidence in Ernexa's strategic direction, particularly after its recent rebranding. The first closing of the funding occurred on April 2, 2025, with a second closure expected after obtaining necessary stockholder approval.

Read more →
-ERNA
Dec 14, 2023
ERNAGeneral

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Eterna Therapeutics Inc. has announced a $9.2 million financing deal involving senior convertible promissory notes and warrants. The company expects to close the initial transaction that will provide approximately $7.8 million in proceeds shortly. This financing is a strategic move to bolster its operations in mRNA cell engineering and other related technologies, though it also raises potential concerns regarding shareholder dilution and the inherent risks of developing innovative biopharma products.

Read more →
-ERNA
Aug 2, 2023
ERNAConferences/Events

Eterna TherapeuticsInvestor Presentation August 2023 1 Eterna Therapeutics Inc. This presentation (this "Presentation") and any oral statements made in connection with this Presentation are for informational purposes onl

Eterna Therapeutics recently held an investor presentation detailing its advancements in mRNA cell engineering and gene editing technologies. The company highlighted its efforts to develop novel therapies for blood cancers, solid tumors, and other conditions utilizing its proprietary platforms. Eterna also emphasized its strong intellectual property position and the potential for substantial market opportunities through collaborations and partnerships. However, the presentation included cautionary notes about the inherent uncertainties in the biotechnology sector.

Read more →
-ERNA
Mar 20, 2023
ERNAGeneral

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited indu

Eterna Therapeutics has reported its financial results for Q4 and the full year 2022, highlighting a net loss of $24.6 million. Significant developments include a license agreement with Lineage Cell Therapeutics, aimed at creating gene-edited therapies, and a new sublease for expanding its operations in Cambridge. The company also announced the appointment of Matt Angel, Ph.D. as its new CEO. Despite these advancements, the report revealed substantial R&D and administrative expenditures.

Read more →
-ERNA
Nov 9, 2022
ERNAConferences/Events

Eterna TherapeuticsCompany Overview November 2022 1 Eterna Therapeutics Inc. Legal notices This presentation (this "Presentation") and any oral statements made in connection with this Presentation are for informational p

Eterna TherapeuticsCompany Overview November 2022 1 Eterna Therapeutics Legal notices This presentation (this "Presentation") and any oral statements made in connection with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicita

Read more →
-ERNA
Jun 17, 2022
ERNAGeneral

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency SAN DIEGO, JUNE 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn" or the "

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency SAN DIEGO, JUNE 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on developi

Read more →
-ERNA
May 31, 2022
ERNAGeneral

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Mee

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting SAN DIEGO, MAY 31, 2022 (GLOBE NEWSWIRE) -- Brookly

Read more →
-ERNA
May 27, 2022
ERNAGeneral

Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q SAN DIEGO, MAY 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) ("

Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form SAN DIEGO, MAY 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the

Read more →
-ERNA
Apr 15, 2022
ERNAGeneral

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results SAN DIEGO, APRIL 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn"), a biopharmaceutical com

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results SAN DIEGO, APRIL 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene edi

Read more →
-ERNA
Mar 9, 2022
ERNAGeneral

Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement New York

Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement New York, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/ce

Read more →
-ERNA
Nov 12, 2021
ERNAConferences/Events

mRNA Engineered Cell & Genetic Medicines November 2021 A platform company in cell, gene-editing & cytokine therapies Disclaimer This presentation is intended to provide summary information about the business of Brooklyn

mRNA Engineered Cell & Genetic Medicines November 2021 A platform company in cell, gene-editing & cytokine therapies Disclaimer This presentation is intended to provide summary information about the business of Brooklyn ImmunoTherapeutics, Inc. ("BTX"). The information in this

Read more →
-ERNA
Oct 14, 2021
ERNAGeneral

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq Ticker Symbol to Remain "BTX"

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq Ticker Symbol to Remain "BTX" NEW YORK, October 14, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gen

Read more →
-ERNA
Sep 20, 2021
ERNAGeneral

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 September 21, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/c

Read more →
-ERNA
Sep 14, 2021
ERNAGeneral

Dear Brooklyn Immunotherapeutics, Inc. ("Brooklyn") Shareholder: We are pleased to announce that Computershare Trust Company, N.A. ("Computershare") has been appointed as the stock transfer agent and registrar for Brookl

www.computershare.com 1-800-736-3001 (U.S.) 1-781-575-3100 (non-U.S.) web.queries@computershare.com Louisville KY 40233-5000 462 South 4th Street Louisville KY 40233-5000 140 58th Street, Building A, Suite 2100, Brooklyn, New York 11220 | tel: (212) 582-1199 | brooklynitx.c

Read more →
-ERNA
Sep 9, 2021
ERNAConferences/Events

September 2021 mRNA Engineered Cell & Cytokine Medicines A platform company in cell, gene-editing & cytokine therapies Disclaimer This presentation is intended to provide summary information about the business of Brookly

September 2021 mRNA Engineered Cell & Cytokine Medicines A platform company in cell, gene-editing & cytokine therapies Disclaimer This presentation is intended to provide summary information about the business of Brooklyn ImmunoTherapeutics, Inc. ("BTX"). The information in th

Read more →
-ERNA
Aug 20, 2021
ERNAConferences/Events

Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum Brooklyn, NY

Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum Brooklyn, NY - August 20, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokin

Read more →
-ERNA
Aug 12, 2021
ERNAGeneral

Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results

Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results August 12, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have in t

Read more →
-ERNA
Jul 19, 2021
ERNAConferences/Events

Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Toda

Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the Transaction

Read more →
-ERNA
Jul 13, 2021
ERNAGeneral

Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer Brooklyn, NY

Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer Brooklyn, NY - July 13, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or "the Company"), a biopharmaceutical company focused on exploring the role that cytokine and gene e

Read more →
-ERNA
Jun 8, 2021
ERNAGeneral

Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer Brooklyn, NY

Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer Brooklyn, NY - June 8, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cel

Read more →
-ERNA
Apr 6, 2021
ERNAGeneral

Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. Brooklyn, NY

Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. Brooklyn, NY - April 6, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or "the Company"), a biopharmaceutical company focused on exploring the role that

Read more →
-ERNA
Mar 23, 2021
ERNAGeneral

NTN Buzztime Announces Proposed Reverse Stock Split Ratio and Anticipated Closing of Merger Carlsbad, CA

Buzztime Announces Proposed Reverse Stock Split Ratio and Anticipated Closing of Merger CA, March 23, 2021 /PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN) today announced that it plans to effect a one for two reverse stock split of its outstanding shares of common stock

Read more →
-ERNA
Mar 15, 2021
ERNAFDA Updates

NTN Buzztime Announces Approval of Merger with Brooklyn Immunotherapeutics by Stockholders at Special Meeting Carlsbad, CA

Buzztime Announces Approval of Merger with Brooklyn Immunotherapeutics by Stockholders at Special Meeting CA, March 15, 2021 / PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN) today announced that its stockholders have approved the proposed merger between NTN and Brooklyn

Read more →
-ERNA
Mar 8, 2021
ERNAGeneral

Independent Advisory Firm ISS Recommends NTN Stockholders Vote FOR Proposed Merger and Asset Sale and ALL Related Proposals

Advisory Firm ISS Recommends NTN Stockholders Vote FOR Proposed Merger and Asset Sale and ALL Related Proposals Calif., March 8, 2021 /PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN) today announced that leading independent proxy advisory firm Institutional Shareholder Se

Read more →
-ERNA
Feb 9, 2021
ERNAPhases

Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer Brooklyn, NY

ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Negative Breast Cancer NY - February 9, 2021 - Brooklyn ImmunoTherapeutics LLC ("Brooklyn"), a biopharmaceutical company focused on exploring the role that c

Read more →
-ERNA
Feb 3, 2021
ERNAGeneral

NTN Buzztime Announces Date of Special Meeting of Stockholders to Vote on Proposed Merger and Asset Sale

Buzztime Announces Date of Special Meeting of Stockholders Vote on Proposed Merger and Asset Sale Calif., Feb. 3, 2021 /PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN), today announced that its registration statement on Form S-4 relating to the proposed merger involving

Read more →
-ERNA
Jan 15, 2021
ERNAGeneral

NTN Buzztime, Inc. Receives Noncompliance Notice from NYSE American

Buzztime, Inc. Receives Noncompliance Notice from NYSE American Calif., January 15, 2021, - NTN Buzztime, Inc. (NYSE American: NTN), announced it received a letter from the NYSE Regulation stating that it is not in compliance with NYSE American LLC continued listing standards.

Read more →
-ERNA
Nov 13, 2020
ERNAGeneral

NTN Buzztime, Inc. Reports Third Quarter 2020 Results

Buzztime, Inc. Reports Third Quarter 2020 Results Calif., November 13, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the third quarter ended September 30, 2020. is working diligently toward closing two transformative transactions," said Allen W

Read more →
-ERNA
Sep 18, 2020
ERNAGeneral

NTN Buzztime Enters Asset Purchase Agreement to Sell Entertainment and Advertising Assets The asset sale complements Buzztime's previously announced proposed reverse merger Carlsbad, CA, September XX, 2020 -NTN Buzztime,

Buzztime Enters Asset Purchase Agreement Sell Entertainment and Advertising Assets CA, September XX, 2020 -NTN Buzztime, Inc. (NYSE American: NTN) signed a definitive asset purchase agreement to sell its social entertainment, customer engagement, and advertising technology ass

Read more →
-ERNA
Aug 13, 2020
ERNAGeneral

NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement -Proposed merger will create a public company focused on the clinical development program of a cytokine-based product for the

Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC into Definitive Merger Agreement merger will create a public company focused on the clinical development of a cytokine-based product for the treatment of cancer company expected to trade on the NYSE American under a new ticke

Read more →
-ERNA
Aug 7, 2020
ERNAGeneral

NTN Buzztime, Inc. Reports Second Quarter 2020 Results

Buzztime, Inc. Reports Second Quarter 2020 Results Calif., August 7, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the second quarter ended negative impact of the COVID-19 pandemic on our customers was abrupt and substantial, and it had a ripple

Read more →
-ERNA
Jun 15, 2020
ERNAGeneral

NYSE Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by September 2021

Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by September 2021 Calif., June 15, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), announced it received a letter from NYSE Regulation, Inc. on June 11, 2020, stating it accepted the company's plan to regain co

Read more →
-ERNA
May 19, 2020
ERNAGeneral

NTN Buzztime, Inc. Reports First Quarter 2020 Results

Buzztime, Inc. Reports First Quarter 2020 Results Calif., May 19, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the first quarter ended March Wolff, CEO, said, "We started 2020 focused on growing our business in an efficient manner. Shifting the

Read more →
-ERNA
Mar 17, 2020
ERNAGeneral

NTN Buzztime, Inc. Reports Fourth Quarter and Full Year 2019 Results

NTN Buzztime, Inc. Reports Fourth Quarter and Full Year 2019 Results CARLSBAD, Calif., March 17, 2020, - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the fourth quarter and year ended December 31, 2019. Allen Wolff, CEO, said, "During the fourth qu

Read more →
-ERNA
Jan 14, 2020
ERNAGeneral

NTN Buzztime Signs Definitive Agreement to Sell Stump! Trivia for $1.4 Million - Continues Emphasis on Digital and Hardware Entertainment Strategy and Divests the Ancillary Hosted Events

Buzztime Signs Definitive Agreement to Sell Stump! Trivia for $1.4 Million Continues Emphasis on Digital and Hardware Entertainment Strategy and Divests the Ancillary Hosted Events - Calif., January 14, 2020, - NTN Buzztime, Inc. (NYSE American: NTN), signed a definitive agreem

Read more →
-ERNA
Nov 26, 2019
ERNAGeneral

NTN Buzztime Appoints Game Development Expert Michael Gottlieb to the Board - Jeff Berg and Steve Mitgang Retire from the Board

Buzztime Appoints Game Development Expert Michael Gottlieb to the Board Jeff Berg and Steve Mitgang Retire from the Board - Calif., November 26, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), appointed game development expert Michael Gottlieb as an independent, non-executive

Read more →
-ERNA
Oct 30, 2019
ERNAGeneral

NTN Buzztime, Inc. Reports Third Quarter 2019 Results - Grew Cash Flow from Operations to $1.8 Million YTD 2019, Up from $528,000 YTD 2018 - - Signed Repeat Customer for $3 Million Hardware Deal - - Secured Hardware Part

Buzztime, Inc. Reports Third Quarter 2019 Results Grew Cash Flow from Operations to $1.8 Million YTD 2019, Up from $528,000 YTD 2018 - Signed Repeat Customer for $3 Million Hardware Deal - Secured Hardware Partnership to Enable Digital Marketing and Loyalty Platform- Calif.,

Read more →
-ERNA
Sep 17, 2019
ERNAGeneral

NTN Announces CEO Transition - Ram Krishnan to Depart; CFO Allen Wolff to Act as Interim CEO

Announces CEO Transition Ram Krishnan to Depart; CFO Allen Wolff to Act as Interim CEO - Calif., September 17, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), announced CEO Ram Krishnan will resign as CEO of the company effective September 17, 2019 and serve as an advisor thr

Read more →
-ERNA
Sep 3, 2019
ERNAGeneral

NTN Announces Board Transition

Announces Board Transition Calif., September 3, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), changed the composition of its board of directors effective August 30, 2019. Gregg Thomas, a current director, was named chair, replacing Jeff Berg, who will remain on the board. S

Read more →
-ERNA
Aug 9, 2019
ERNAGeneral

NTN Buzztime, Inc. Reports Second Quarter 2019 Results - Signs Repeat Customer for $3 Million Deal - - Increases Footprint with Mobile App

Buzztime, Inc. Reports Second Quarter 2019 Results Signs Repeat Customer for $3 Million Deal - Increases Footprint with Mobile App - Calif., August 9, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the second quarter ended the second quarter,

Read more →
-ERNA
May 13, 2019
ERNAGeneral

NTN Buzztime, Inc. Reports First Quarter 2019 Results Launches Buzztime Entertainment App in Open Beta Expanding Target Market

Buzztime, Inc. Reports First Quarter 2019 Results Buzztime Entertainment App in Open Beta Expanding Target Market Calif., May 13, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the first quarter ended Buzztime continues to evolve, we remain com

Read more →
-ERNA
Mar 20, 2019
ERNAGeneral

NTN Buzztime, Inc. Reports Fourth Quarter and Full Year 2018 Results - Grew Q4 2018 Revenue 12% to $5.9 Million - - Reported Q4 2018 GAAP Net Income Attributable to Common Shareholders of $44,000 - - Posted $732,000 in Q

Buzztime, Inc. Reports Fourth Quarter and Full Year 2018 Results Grew Q4 2018 Revenue 12% to $5.9 Million - Reported Q4 2018 GAAP Net Income Attributable to Common Shareholders of $44,000 - Posted $732,000 in Q4 2018 EBITDA, Marking Eleventh Consecutive Quarter Positive - Cal

Read more →
-ERNA
Dec 7, 2018
ERNAGeneral

NTN Buzztime Exploring Strategic Alternatives

Buzztime Exploring Strategic Alternatives Calif., December 7, 2018 - NTN Buzztime, Inc. (NYSE American: NTN) today announced that its board of directors is exploring and evaluating strategic alternatives focused on maximizing shareholder value, including, among other things, a

Read more →
-ERNA
Nov 7, 2018
ERNAGeneral

NTN Buzztime, Inc. Reports Third Quarter 2018 Results - Grew Revenue 15.5% to $6.0 Million, Up from $5.2 Million Q3 2017 - - Recorded GAAP Net Income of $222,000 - - Posted $1.1 Million in EBITDA, Marking Tenth Consecuti

Buzztime, Inc. Reports Third Quarter 2018 Results Grew Revenue 15.5% to $6.0 Million, Up from $5.2 Million Q3 2017 - Recorded GAAP Net Income of $222,000 - Posted $1.1 Million in EBITDA, Marking Tenth Consecutive Quarter Positive - Calif., November 7, 2018, - NTN Buzztime, In

Read more →
-ERNA
Aug 2, 2018
ERNAGeneral

NTN Buzztime, Inc. Reports Second Quarter 2018 Results - Grew Revenue to $5.7 Million, Up from $5.5 Million Q2 2017 - - Improved GAAP Net Loss to $124,000 and Achieved Ninth Consecutive Quarter of Positive EBITDA

Buzztime, Inc. Reports Second Quarter 2018 Results Grew Revenue to $5.7 Million, Up from $5.5 Million Q2 2017 - Improved GAAP Net Loss to $124,000 and Achieved Ninth Consecutive Quarter of Positive EBITDA - Calif., August 2, 2018, - NTN Buzztime, Inc. (NYSE American: NTN), re

Read more →
-ERNA
Jun 27, 2018
ERNAGeneral

NTN Buzztime Announces $1.6 Million Registered Direct Offering of Common Stock

Buzztime Announces $1.6 Million Registered Direct Offering of Common Stock Calif., June 27, 2018 - NTN Buzztime, Inc. (NYSE MKT: NTN) today announced that it has entered into a subscription agreement with certain investors relating to a registered direct offering in which the c

Read more →
-ERNA
May 9, 2018
ERNAGeneral

NTN Buzztime, Inc. Reports First Quarter 2018 Results - Grew Revenue to $5.8 Million, Up 10% from Q1 2017 - - Improved Gross Margins to 66%, Up from 65% in Q1 2017 - - Achieved Eighth Consecutive Quarter of Positive EBIT

Buzztime, Inc. Reports First Quarter 2018 Results Grew Revenue to $5.8 Million, Up 10% from Q1 2017 - Improved Gross Margins to 66%, Up from 65% in Q1 2017 - Achieved Eighth Consecutive Quarter of Positive EBITDA - Calif., May 9, 2018, - NTN Buzztime, Inc. (NYSE American: NTN

Read more →
-ERNA
Apr 30, 2018
ERNAGeneral

NYSE Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by March 2019

Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by March 2019 Calif., April 30, 2018 - NTN Buzztime, Inc. (NYSE American: NTN), leader in interactive entertainment and innovative dining technology to bars and restaurants in North America, announced it receiv

Read more →
-ERNA
Mar 6, 2018
ERNAGeneral

NTN Buzztime, Inc. Reports Fourth Quarter and Full Year 2017 Results - Annual Gross Margins of 68%, up from 65% in 2016 - - Seventh consecutive quarter of positive EBITDA

Buzztime, Inc. Reports Fourth Quarter and Full Year 2017 Results Annual Gross Margins of 68%, up from 65% in 2016 - Seventh consecutive quarter of positive EBITDA - Calif., March 6, 2018, 2017 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the fourth

Read more →
-ERNA
Nov 7, 2017
ERNAGeneral

NTN Buzztime, Inc. Reports Third Quarter 2017 Results - Gross Margin reaches 70%

NTN Buzztime, Inc. Reports Third Quarter - Gross Margin reaches CARLSBAD, Calif., November 7, 2017 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the third quarter ended September 30, 2017. "During the third quarter, we continued executing consiste

Read more →
-ERNA
Aug 2, 2017
ERNAGeneral

NTN Buzztime, Inc. Reports Second Quarter 2017 Results

Buzztime, Inc. Reports Second Quarter 2017 Results Calif., August 2, 2017 - NTN Buzztime, Inc. (NYSE American: NTN) reported financial results for the second quarter ended June 30, 2017. Recorded GAAP net loss of $164,000 in Q2 2017, a $686,000 improvement compared to Q2 2016

Read more →
-ERNA
Jul 10, 2017
ERNAGeneral

NTN Buzztime Appoints Two New Independent Members to the Board of Directors

Buzztime Appoints Two New Independent Members the Board of Directors Calif., July 10, 2017- NTN Buzztime, Inc. (NYSE MKT: NTN) appointed independent directors Gregg Thomas, 56, and Richard Simtob, 47, to its board of directors effective July 7, 2017. They will replace Mary Bet

Read more →
-ERNA
May 3, 2017
ERNAGeneral

NTN Buzztime, Inc. Reports First Quarter 2017 Results -Records GAAP Net loss of $90,000, a $1 million improvement compared to 2016 - -Reports positive EBITDA for fourth consecutive quarter - Completes financing initiativ

Buzztime, Inc. Reports First Quarter 2017 Results GAAP Net loss of $90,000, a $1 million improvement compared to 2016 - positive EBITDA for fourth consecutive quarter Completes financing initiatives, anticipates regaining NYSE MKT listing compliance - Launches Spaceteam multi

Read more →
-ERNA
Apr 25, 2017
ERNAGeneral

NTN Buzztime Announces Registered Direct Offering of Common Stock

Buzztime Announces Registered Direct Offering of Common Stock Calif., April 25, 2017 - NTN Buzztime, Inc. (NYSE MKT: NTN) today announced that before the market opened today it entered into a subscription agreement with certain investors relating to a registered direct offering

Read more →
-ERNA
Mar 6, 2017
ERNAGeneral

NTN Buzztime, Inc. Expands Partnership with Buffalo Wild Wings and Reports Fourth Quarter and Year-end 2016 Results - Improves 2016 Net Loss by $4.3 million compared to 2015 - - Buzztime Selected to Deliver Order and Pay

NTN Buzztime, Inc. Expands Partnership with Buffalo Wild Wings and Reports Fourth Quarter and Year-end 2016 - Improves 2016 Net Loss by $4.3 million compared to 2015 - - Buzztime Selected to Deliver Order and Pay with EMV Functionality to Buffalo Wild Wings - CARLSBAD, Cal

Read more →
-ERNA
Nov 8, 2016
ERNAGeneral

NTN Buzztime, Inc. Reports Third Quarter 2016 Results - Receives $2.7 Million in Net Proceeds Subsequent to Quarter End - - Improves Net Loss to $573,000, Compared to Net Loss of $1.3 Million in the Third Quarter 2015

NTN Buzztime, Inc. Reports Third Quarter - Receives $2.7 Million in Net Proceeds Subsequent to Quarter End - to $573,000, Compared to Net Loss of $1.3 Million in the Third Quarter 2015 - CARLSBAD, Calif., November 8, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financ

Read more →
-ERNA
Aug 3, 2016
ERNAGeneral

NTN Buzztime, Inc. Reports Second-Quarter 2016 Results - Improves Net Loss by $1.8 million to $850,000, Compared to Second Quarter 2015 - - Generates over $500,000 in Quarterly Cash from Operations

Reports Second-Quarter 2016 Results Net Loss by $1.8 million to $850,000, Compared to Second Quarter 2015 - over $500,000 in Quarterly Cash from Operations - CARLSBAD, Calif., August 3, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the second quart

Read more →
-ERNA
Jun 7, 2016
ERNAGeneral

Buzztime Announces Anticipated Effective Date of Reverse/Forward Stock Split Carlsbad, CA

Announces Anticipated Effective Date of Reverse/Forward Stock Split CA - June 7, 2016 - NTN Buzztime, Inc. (NYSE MKT:NTN), a leader in interactive entertainment and innovative dining technology, today announced the expected effective date of its 1-for-100 reverse stock split (t

Read more →
-ERNA
May 6, 2016
ERNAGeneral

NTN Buzztime, Inc. Reports First-Quarter 2016 Results - Launches Order and Payment at Buffalo Wild Wings - - Delivers Better than Expected First Quarter with Positive Adjusted EBITDA

Reports First-Quarter 2016 Results Order and Payment at Buffalo Wild Wings - Better than Expected First Quarter with Positive Adjusted EBITDA - CARLSBAD, Calif., May 6, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the first quarter ended March 31,

Read more →
-ERNA
Mar 11, 2016
ERNAGeneral

NTN Buzztime, Inc. Amends Credit Agreement, Increasing Access to Short-term Capital

Buzztime, Inc. Amends Credit Agreement, Increasing Access to Short-term Capital Calif., March 11, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), a leader in interactive entertainment and innovative dining technology, amended its credit agreement with East West Bank to increase the

Read more →
-ERNA
Mar 11, 2016
ERNAGeneral

NTN Buzztime, Inc. Reports Fourth-Quarter 2015 Results - Achieves Adjusted EBITDA Positive for Fourth Quarter 2015

Buzztime, Inc. Reports Fourth-Quarter 2015 Results Achieves Adjusted EBITDA Positive for Fourth Quarter 2015 - Calif., March 11, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the fourth quarter and year ended December 31, 2015. was a pivotal year f

Read more →
-ERNA
Feb 11, 2016
ERNAConferences/Events

PRESENTATION Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, p

Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, product and platform development, new revenue, customer development, impro

Read more →
-ERNA
Feb 2, 2016
ERNAGeneral

NYSE Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by May 2017

Plan for NTN Buzztime, Inc. to Regain Compliance by May 2017 CARLSBAD, Calif., February 2, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), leader in interactive entertainment and innovative dining technology to bars and restaurants in North America, announced it received a letter f

Read more →
-ERNA
Jan 28, 2016
ERNAGeneral

NTN Buzztime, Inc. Preannounces Fourth-Quarter 2015 Metrics -Increased site count for the third quarter in a row- -Expects to be Adjusted EBITDA Positive for Fourth Quarter 2015

Inc. Preannounces Fourth-Quarter 2015 Metrics site count for the third quarter in a row- to be Adjusted EBITDA Positive for Fourth Quarter 2015- CARLSBAD, Calif., January 28, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), today announced preliminary Adjusted EBITDA for the fourth

Read more →
-ERNA
Dec 2, 2015
ERNAConferences/Events

Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, product and pl

Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, product and platform development, new revenue, customer development, impro

Read more →
-ERNA
Nov 16, 2015
ERNAGeneral

NTN Buzztime, Inc. Receives Noncompliance Notice from

NTN Buzztime, Inc. Receives Noncompliance Notice from NYSE MKT CARLSBAD, Calif., November 16, 2015 - NTN Buzztime, Inc. (NYSE MKT: NTN), leader in interactive entertainment and innovative dining technology to bars and restaurants in North America, announced it received of a l

Read more →
-ERNA
Nov 5, 2015
ERNAGeneral

NTN Buzztime, Inc. Reports Third-Quarter 2015 Results -Increased site count for the second quarter in a row- -Signed two master service agreements with experience-focused chains- -Deployed payment capabilities with estab

NTN Buzztime, Inc. Reports Third-Quarter -Increased site count for the second quarter in a row- -Signed two master service agreements with experience-focused chains- capabilities with established partner venue- CARLSBAD, Calif., November 5, 2015 - NTN Buzztime, Inc. (NYSE M

Read more →
-ERNA
Aug 6, 2015
ERNAGeneral

NTN Buzztime, Inc. Reports Second-Quarter 2015 Results - Grew revenue 8% sequentially

NTN Buzztime, Inc. Reports Second-Quarter - Grew revenue 8% sequentially CARLSBAD, Calif., August 6, 2015 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the second quarter ended June 30, 2015. "Second quarter revenue grew 8% sequentially, reflecting pos

Read more →
-ERNA
May 7, 2015
ERNAGeneral

NTN Buzztime, Inc. Reports First-Quarter 2015 Results - The BEOND Platform Reaches 43% of the Installed Base - - Aligns Business to Key Initiatives and Reduces Future Operating Expenses

NTN Buzztime, Inc. Reports First-Quarter - The BEOND Platform Reaches 43% of the Installed Base - - Aligns Business to Key Initiatives and Reduces Future Operating Expenses - CARLSBAD, Calif., May 7, 2015 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for

Read more →
-ERNA
Apr 16, 2015
ERNAGeneral

NTN Buzztime, Inc. Secures New Credit Agreement - Increases financial flexibility and reduces interest obligation

NTN Buzztime, Inc. Secures New - Increases financial flexibility and reduces interest obligation - CARLSBAD, Calif., April 16, 2015 - NTN Buzztime, Inc. (NYSE MKT: NTN), a leading provider of in-venue social gaming and entertainment, announced the closing of a three-year rev

Read more →
-ERNA
Mar 26, 2015
ERNAGeneral

NTN Buzztime, Inc. Reports Fourth-Quarter and Full-Year 2014 Results - The BEOND Platform Reaches 1,106 Sites, 37% of the Installed Base at Q4 2014 Close

NTN Buzztime, Inc. Reports Fourth-Quarter and Full-Year 2014 Results - The BEOND Platform Reaches 1,106 Sites, 37% of the Installed Base at Q4 2014 Close - CARLSBAD, Calif., March 26, 2015 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the fourth-quarte

Read more →
-ERNA
Dec 19, 2014
ERNAGeneral

NTN Buzztime Names Allen Wolff Chief Financial Officer

NTN Buzztime Names Allen Wolff Chief CARLSBAD, Calif., December 19, 2014 - NTN Buzztime, Inc. (NYSE MKT: NTN) hired Allen Wolff, 42, as chief financial officer effective December 29, 2014. Wolff, among other responsibilities, will assume the principal accounting duties and rep

Read more →
-ERNA
Mar 11, 2014
ERNAGeneral

WE ENTERTAIN CONSUMERS IN WAYS THAT CREATE LONG TERM VALUE FOR MERCHANTS. WE PUT PLAY TO WORK. Ticker: NTN Exchange

WE ENTERTAIN CONSUMERS IN WAYS THAT CREATE LONG TERM VALUE FOR MERCHANTS. WE PUT PLAY TO WORK. Ticker: NTN Exchange: NYSE MKT March 11, 2014 This presentation includes statements that may constitute "forward - looking statements," including estimates of future business prospects

Read more →
-ERNA
Mar 28, 2013
ERNAGeneral

PRESS RELEASE ntn_8kex99-1.htm

Chief Financial Officer CCG Investor Relations NTN Buzztime, Inc. Announces Fourth Quarter and Full Year 2012 Results CARLSBAD, Calif., March 28, 2013 - NTN Buzztime, Inc. (NYSE MKT: NTN) today announced results for the fourth quarter and year ended December 31, 2012. "In the

Read more →
Competitive Position
How ERNA ranks across every disease it competes in
Competitive Position is a premium feature
See how ERNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial